Korro Bio partners with Novo Nordisk for up to $530M in RNA editing deal for cardiometabolic targets

Korro Bio, Inc.

Up to $530M in upfront, development, and commercial milestone payments plus tiered royalties and R&D funding.
Upfront fee of $10M for first target; potential additional upfront for second target if nominated.
Korro grants exclusive worldwide license to Novo Nordisk for two undisclosed cardiometabolic targets using OPERA platform.
Korro responsible for preclinical development; Novo Nordisk may advance programs through clinical studies.
Deal allows Korro to retain internal pipeline focus while expanding RNA editing to high-prevalence diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.